title: Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
abstract: Anaemia is a common in chronic kidney disease. Although erythropoietin and iron supplementation are established treatments, knowledge on the use of IV iron alone in patients not on dialysis or erythropoietin is incomplete. The responses of 82 patients referred to the renal anaemia service with haemoglobin of 11.5 g/dl or less were assessed 1 week after completing four once weekly doses of 200 mg of venofer. No patients were on dialysis or erythropoietin. The haemoglobin rise 1 week after treatment was 0.53 g/dl. Ferritin levels improved from 110.8 to 410.2 ng/l and transferrin saturation from 17.7 to 27.3%. Ferritin levels remained below our target range (200-500 ng/l) in 7.7% while 25.6% had levels above this. Ferritin levels remained less than 800 ng/l in nearly all patients. Intravenous iron is cost effective and should be considered for use in patients with renal anaemia. Patients with CKD stage 5 appeared to respond less well.
authors.affiliation: Department of Nephrology, University Hospital of North Staffordshire, Royal Infirmary, Stoke on Trent, United Kingdom. senyo.tagboto@uhns.nhs.uk
authors.forename: Senyo
authors.initials: S
authors.lastname: Tagboto
authors.forename: Liz
authors.initials: L
authors.lastname: Cropper
authors.forename: Samiul
authors.initials: S
authors.lastname: Mostafa
authors.forename: June
authors.initials: J
authors.lastname: Turner
authors.forename: Georgina
authors.initials: G
authors.lastname: Bailey
authors.forename: Karen
authors.initials: K
authors.lastname: Pugh-Clarke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood / Q000187:drug effects; D005919:Glomerular Filtration Rate; D005937:Glucaric Acid; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012720:Severity of Illness Index; D013395:Sucrose / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D014168:Transferrin / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D006454:Hemoglobins; D014168:Transferrin; D004921:Erythropoietin; D013395:Sucrose; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid